---
document_datetime: 2025-12-02 05:17:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/wayrilz.html
document_name: wayrilz.html
version: success
processing_time: 0.040739
conversion_datetime: 2025-12-28 11:24:43.682
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Wayrilz

[RSS](/en/individual-human-medicine.xml/268871)

##### Opinion

EMA has issued an opinion on this medicine

rilzabrutinib Medicine Human Opinion

Page contents

## Page contents

- [Overview](#overview)
- [Product details](#product-details)
- [News on Wayrilz](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 16 October 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Wayrilz, intended for the treatment of immune thrombocytopenia (ITP) in adults who are refractory to other treatments.

The applicant for this medicinal product is Sanofi B.V.

Wayrilz will be available as 400 mg film-coated tablets. The active substance of Wayrilz is rilzabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor (ATC code: not yet assigned). Rilzabrutinib mediates its therapeutic effect through multi-immune modulation by inhibiting B cell activation, interrupting FcÎ³R mediated phagocytosis, and potentially ameliorating chronic inflammation associated with ITP.

The benefits of Wayrilz include a significantly higher rate of durable platelet response in adults with ITP refractory to other treatments compared with placebo, especially when used in combination with corticosteroids and/or thrombopoietin receptor agonists, as shown in a phase 3 multicentre, randomised, double-blind, placebo-controlled study. The most common side effects with Wayrilz include diarrhoea, nausea, headache, COVID-19, abdominal pain, arthralgia and nasopharyngitis.

The full indication is:

Wayrilz is indicated for the treatment of immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.

Treatment with Wayrilz should be initiated and remain under the supervision of physicians experienced in the treatment of haematological diseases.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Note: This product was designated as an orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained

CHMP summary of positive opinion for Wayrilz

Adopted

Reference Number: EMA/CHMP/228349/2025

English (EN) (137.96 KB - PDF)

**First published:** 17/10/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-wayrilz_en.pdf)

## Product details

Name of medicine Wayrilz Active substance rilzabrutinib International non-proprietary name (INN) or common name rilzabrutinib Therapeutic area (MeSH) Purpura, Thrombocytopenic, Idiopathic Anatomical therapeutic chemical (ATC) code Not yet assigned EMA product number EMEA/H/C/006425

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation applicant Sanofi B.V. Opinion adopted 16/10/2025 Opinion status Positive

#### News on Wayrilz

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 October 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-october-2025) 17/10/2025

**This page was last updated on** 17/10/2025

## Share this page

[Back to top](#main-content)